BACKGROUND: Hyperglycemia is commonly encountered in critically ill patients and is associated with increased mortality and morbidity. To better control blood glucose levels, we previously developed a new computerized fading memory (FM) algorithm.
H yperglycemia is commonly encountered in critically ill patients as a result of stress-induced counterregulatory hormones and impairment of glucose metabolism and is associated with adverse clinical outcome. [2] [3] [4] [5] Optimal glucose control within a certain target range using IV insulin infusion has been demonstrated to improve mortality and morbidity in critically ill patients. [2] [3] [4] [5] [6] [7] Van den Berghe et al. reported in 2001 6 that intensive insulin therapy (IIT) decreased mortality among patients admitted to the surgical intensive care unit (SICU). However, similar studies 8 -11 that were subsequently conducted have produced conflicting results. Recently, the NICE-SUGAR Study concluded that IIT increased the risk of hypoglycemia and mortality. 10 We suggest that besides the relatively low target glucose level (80 to 110 mg/dL), 12, 13 the conventional algorithms used for IIT could also have increased the chances of hypoglycemia. Originally, these algorithms were developed on the basis of clinical experience to attain higher target glucose levels with less frequent blood glucose measurements. Hence, the algorithms were implicitly "optimized" for glucose control needs, target glucose level, and lower sampling frequency that existed before the IIT studies. Therefore, use of the conventional algorithms, without accurately scaling for the lower target glucose levels and higher sampling frequency requirements of IIT, would lead to a suboptimal approach, resulting in increased chances of hypoglycemia.
Glycemic variability has been shown to be a strong independent risk factor for mortality in critically ill patients. 14, 15 This has led to recommendations that a decrease in the variability of blood glucose levels should be as important as absolute glucose level in perioperative glucose management. 3, 4 Thus an optimal glucose control algorithm should not only lower glucose levels to a desired target range, but also maintain the level with minimal fluctuations. The physiologic dynamics of insulin secretion have been investigated, with several studies demonstrating glucoseinduced biphasic patterns of insulin release with dynamic regulation. 16 -19 The pancreatic cell response is characterized by an initial, transient but rapid increase in insulin secretion, followed by a slower increase that remains elevated for the duration of hyperglycemia. [17] [18] [19] However, after several hours, there is little or no continued increase in insulin secretion despite the persistence of hyperglycemia. 18 We hypothesized that an algorithm for glycemic control should be designed to duplicate the same physiologic functions of pancreatic cells. 1 Such an algorithm should emulate what "nature" has refined and determined to be optimal. Following this hypothesis, we developed a fading memory (FM) proportional derivative control algorithm that emulates the pancreatic response. 1 The FM algorithm is based on control system theory and is a modified proportional derivative control algorithm. It analyzes not only the current but also information from previous glucose levels to prescribe optimal insulin doses for effective and safe glucose control. Additionally, the FM algorithm dynamically adjusts its parameters to varying insulin sensitivity, thus customizing itself to different patient characteristics and surgical stress conditions. Lastly, the algorithm is scalable, allowing different glucose measurement frequencies and target levels. The FM algorithm has been validated in a rat model. 1 Our current study was designed to evaluate the basic safety and feasibility of the FM algorithm for glucose control in humans and compare it with the conventional insulin infusion algorithm.
METHODS

Setting, Patient Population, and Informed Consent
This was a single-centered, prospective, randomized, control study conducted in a 10-bed SICU of the Veterans Affairs (VA) Puget Sound Health Care System (PSHCS), Seattle, WA. The IRB of VA PSHCS approved the research protocol and consent forms. Adult patients, 18 years and older, scheduled for elective surgery with subsequent elective postoperative admission to the SICU, were included. Written informed consent was obtained from all participants preoperatively. Once informed consent was obtained, the demographic and clinical characteristics of the patient, such as age, gender, body weight, body mass index (BMI), type of surgery, ASA classification, history of diabetes, diabetic medications (oral hypoglycemic drugs, insulin), and laboratory data were recorded. Recruited patients were randomly assigned to receive either the VA insulin algorithm (group VA) or the FM algorithm (group FM) using covariate adaptive randomization.
20,21
Power Calculations A power calculation was conducted to detect differences between the 2 algorithms in the mean steady state error in the glucose level. Steady state error was defined as the mean absolute difference of the hourly glucose level from the target level (140 mg/dL) during the maintenance period. We assumed a mean steady state error of 20 mg/dL for the VA algorithm and 10 mg/dL for the FM algorithm.
An SD of steady state error was assumed to be 10 mg/dL for the VA algorithm and 5 mg/dL for the FM algorithm. Applying 2-sided, 2-sample, t test with unequal variances, we determined that approximately 27 subjects per group would be needed to achieve 90% power at P Ͻ 0.05 significance level. Availability of limited resources forced us to limit the sample size to 50 subjects before exclusions.
FM Algorithm
The FM algorithm uses the current and the previous glucose measurements to determine an insulin infusion rate to bring the glucose level to a target level. The glucose measurements are weighed in an exponentially decaying fashion such that the more recent measurements are weighed more than are the less recent ones. In processing a "fading history" of glucose levels, the algorithm tries to emulate the pancreatic response to blood glucose level changes. The mathematical basis of this algorithm is described in the Appendix. Figure 1 shows the biphasic insulin dose response of the FM algorithm for a step change in glucose level. This response is quite similar to that of a normal pancreas. [17] [18] [19] The basic form of this algorithm was previously developed using computer models and later validated in rat models. 1 
VA Puget Sound Insulin Infusion Algorithm
Our institution uses a paper-based insulin infusion algorithm that was adopted from the one developed and used at the University of Washington. The algorithm is primarily based on a table that prescribes an insulin infusion rate based on the current glucose level. The specific details of the algorithm are given in Figure 2 .
Software Preparation
The FM algorithm was refined to suit glucose control in the ICU. Specifically, the algorithm was scaled to accommodate a sampling rate of 1 glucose measurement per hour. Additionally, the algorithm was refined to suit the ICU patient population on the basis of published glucose-insulin homeostasis parameters for human patients. 19, [22] [23] [24] [25] [26] [27] Specifically, the gain parameters were scaled to a have a better starting point for human patients. The FM and the VA insulin algorithms were implemented as part of a computer program. The program ran on a laptop computer at the patient's bedside and prescribed an insulin infusion rate based on the selected algorithm. The measured glucose values were input manually into the program to obtain the next insulin infusion rate. The computer program was developed in Labview programming environment (National Instruments Inc., Austin, TX). The user interface of the program is shown in Figure 3 .
Glucose Control Protocol
A target glucose level of 140 Ϯ 20 mg/dL was used for the study. This was the same target being used at our institution before the study. On SICU admission, blood glucose was checked, and if it exceeded 140 mg/dL, insulin infusion was initiated. Alternately, if insulin infusion was started in the operating room, it was continued in the SICU. For these cases "time 0" was defined as when the first Figure 2 . VA insulin infusion protocol used in SICU glucose management. The protocol uses a table that maps measured glucose levels to insulin infusion rates. The glucose measurements are made hourly, and the chart is consulted to obtain the new insulin infusion rate. Evaluation of Computerized Glucose Control Algorithm glucose level was measured in the SICU. The decision to initiate intraoperative glucose control using the VA paper algorithm was made by the anesthesia providers. Initiation or continuation of insulin infusion followed either the FM or VA algorithm according to randomization. Regular insulin was dissolved in normal saline at a concentration of 1 U/mL and was infused with an IVAC infusion pump (Alaris Pump, Ardus Medical Inc., Cincinnati, OH). Arterial blood glucose levels were measured using an accurate point-of-care glucose monitor (Accu-chek, Roche Diagnostics Corp., Indianapolis, IN) on an hourly basis by the bedside nurse. The glucose values were manually entered into the computer program, which then computed an insulin dose on the basis of the selected control algorithm. When a change in insulin infusion rate was prescribed by the computer program, the bedside nurse manually adjusted the infusion pump to the new infusion rate. The protocol was applied for 8 hours starting from the point of initiation of insulin infusion after ICU admission. Upon the completion of the study protocol, the VA algorithm was followed in a manual fashion. Glucose levels lower than 60 mg/dL was considered hypoglycemic, and levels higher than 300 mg/dL were considered excessively hyperglycemic.
Statistical Analysis
Patient demographics were compared for each group (groups VA and FM) with mean Ϯ SD computed for continuous variables and parameter counts Ϫ N (%) computed for categorical variables. Differences in patient demographics between the 2 groups were tested with the 2-sample t test with unequal variances (continuous variables), the 2 test (categorical variables, when all expected counts in the contingency table were Ն5), or the Fisher exact test (categorical variables, when some expected counts in the contingency table were Ͻ5).
Four parameters were used to compare the VA and FM algorithms: (1) time to reach target glucose level, (2) percentage of glucose measurements that were within target range (120 to 160 mg/dL) after target has been reached, (3) pooled within-patient variability (SD) of glucose levels once target is reached, and (4) mean insulin infusion rate. The nonparametric Mann-Whitney test was used to compare the time to reach the target glucose level. A binomial generalized linear mixed model 28 with a random effect for the patient, and fixed effects for the algorithm and the glucose sampling hour, was used to compare the percentage of glucose measurements within the target between the 2 algorithms. The likelihood ratio test for the difference in within-patient SD in a linear mixed model 29 (with a random effect for the patient) was used to compare the pooled within-patient variability (SD) of glucose levels. A linear mixed model 29 with a random effect for the patient, and fixed effects for the algorithm and the glucose sampling hour, was used to compare the mean insulin rate. The 95% confidence intervals (CIs) for the differences in each of the 4 parameters were calculated using either the nonparametric bootstrap (time to reach target glucose level) or the parametric bootstrap (the remaining 3 parameters) with 999 resamples. 30 All analyses were performed using software, R version 2.12 0.0 (Vienna, Austria). A P value Ͻ0.05 was used to denote statistical significance.
RESULTS
Forty eight patients were enrolled and randomly assigned to receive either the VA insulin infusion algorithm (group VA) or the FM algorithm (group FM). The clinical and demographic characteristics of the 2 groups are shown in Table 1 . Both groups had similar demographics including age, body weight and BMI, and preoperative glucose levels and hemoglobin A1c (HbA1C) (P Ͼ 0.30). Additionally, the proportions of patients who had type 2 diabetes and cardiac surgery were also similar (P ϭ 0.82 and P ϭ 0.85, respectively).
Insulin infusion was initiated in the operating room and continued upon SICU admission in 15 patients in group FM and 18 patients in group VA. The proportions of the patients who received insulin infusion in the operating room were not statistically different between the 2 groups (P ϭ 0.62, 2 test). There was no statistically significant difference in the starting glucose levels between the groups ( Table 2 ). The prescribed initial insulin infusion rate was higher for the FM group when compared with the VA group. When using the VA algorithm, there was 1 incidence of hypoglycemia (Ͻ60 mg/dL), but there were none when using the FM algorithm. For both algorithms there was no incidence of excessive hyperglycemia (Ͼ300 mg/dL). The VA algorithm was unable to reach the target range (140 Ϯ 20 mg/dL) in 3 patients. On the other hand, the target range was always reached when using the FM algorithm.
The individual glucose profiles (smoothed) and the average time course of hourly glucose and insulin values during the study period are shown in Figures 4 and 5 , respectively. It is observed from Figure 4 that the time to reach the target range was less for the FM algorithm when compared with the VA algorithm. The mean insulin profile shows that starting insulin doses were slightly higher for the FM algorithm (4.2 Ϯ 2.0 U/h) when compared with the VA algorithm (3.3 Ϯ 2.7 U/h). However, as time progressed, the amount of insulin prescribed by the FM algorithm was less by approximately 1.5 U/h. To quantitatively compare the VA and FM algorithms, we defined and computed 4 parameters that can measure the ideal algorithm behavior. The comparison of these parameters is summarized in Table 3 . Time to reach target. Time to reach target was measured as the time required to bring the glucose level to the target range after initiating either the VA or FM algorithm. Three patients in group VA did not reach the target levels during the study period of 8 hours. Among the remaining patients, the time to reach target (mean Ϯ SE) was 3.6 Ϯ 0.6 hours for the VA algorithm, but it was 2.8 Ϯ 0.3 hours for the FM algorithm. However, this difference was not statistically significant (P ϭ 0.76). Glucose within target during maintenance. Maintenance of glucose levels within the target range is a desired feature of a glucose control algorithm. The algorithms were compared on the basis of their abilities to keep the glucose level within the target range during the maintenance phase (period after target glucose was first achieved). The FM algorithm resulted in a higher percentage of glucose levels in the normal range (71%) in comparison with the VA algorithm (59%) during the maintenance phase. Overall odds ratio for FM, in comparison with VA for the risk of being in the normal range during the maintenance period, was 1.76 (95% CI, 0.79 -4.59) and statistically not significant (P ϭ 0.16). Within-patient variability of glucose levels during maintenance. The ability to maintain glucose levels with minimal glycemic variability is a measure of algorithm stability. The within-patient SD of glucose levels during the maintenance phase was used as a measure of glycemic variability. The FM algorithm had 28% less glycemic variability when compared with the VA algorithm with the respective standard deviations shown in Table 3 (P Ͻ 0.001). Mean insulin dosage. The comparison of mean hourly insulin infusion rate during the entire period of glucose control (8 hours) shows that, on average, the FM algorithm uses 1.12 U/h of insulin less than the VA algorithm (P ϭ 0.043). Closer inspection revealed that this difference is time dependent, with the difference more pronounced during the later stages of glucose control (Fig. 5) . During the initial stages, when the algorithms attempted to bring the glucose values from the starting level to the target range, the difference in the mean insulin doses was small (difference of means, VA Ϫ FM ϭ Ϫ0.22 U/h) and statistically not significant (P ϭ 0.82). However, during the maintenance phase, the VA algorithm required more insulin than the FM algorithm (difference of means, VA Ϫ FM ϭ 1.65 U/h, P ϭ 0.0028).
DISCUSSION
In this study we compared the performance of a novel glucose control algorithm against a conventional one in postsurgical ICU patients. Though previously tested in computer and rat models, 1 this is the first study in which the FM algorithm was applied to human surgical patients. Our study showed that the FM algorithm was able to control glucose without encountering any incidence of hypoglycemia and excessive hyperglycemia. For the 23 patients who used the FM algorithm, glucose levels were brought within target range in 8 hours or less. However, with the VA algorithm, 3 out of 25 patients did not attain the target glucose range during the study period of 8 hours. We observed that the FM algorithm brought the glucose level from the starting value to the target 0.7 hour earlier than did the VA algorithm. Once the target was reached, we also observed that the FM algorithm maintained 11% more of the glucose levels within the desired range (120 to 160 mg/dL) than did the VA algorithm. However, these differences were also not statistically significant.
The ability to maintain glucose levels without large glycemic variability is important to minimize the risk of hypoglycemia. This is well supported by studies that have shown that glycemic variability can be a significant and independent predictor of ICU and hospital mortality. 14, 15 Glycemic variability, during the maintenance period, measured by the within-patient SD of glucose levels, was lower by 28% when using the FM algorithm in comparison with the VA algorithm. Another observation that is evident from Figure 4 is that the VA algorithm uses significantly more insulin during the maintenance phase. Large insulin doses, after reaching the target, increase the risk of hypoglycemia. The FM algorithm may be comparatively safer with reduced risk of hypoglycemia because it has less glycemic variability and fewer insulin requirements.
Limitations of the study include a small patient population (48 patients) and a short glucose control period (8 hours) . This may have affected the statistical comparison of the algorithms. For the parameters, time to reach the target range, and percentage of glucose measurements within target range, we could not reject the null hypothesis of equality of the 2 algorithms, although the observed differences between the algorithms were nontrivial. A future study in which the algorithms are applied on a larger patient population for a longer duration may be needed to validate some of the results that our study indicated but could not be proven with sufficient confidence.
Another limitation of this study was that the protocol was not blinded. The computer program that executed the algorithms did not perform randomization. Thus, the randomly selected algorithm needed to be specified in the computer program before its execution. However, the SICU nurse who measured the blood glucose levels and made changes to the insulin dose was not aware of which algorithm was being used.
Our study used a target of 140 mg/dL for blood glucose control. This was the same target that our hospital used for postsurgical ICU patients at the time of the study. Previous studies 6, 12 that conducted intensive insulin therapy used more aggressive target levels that ranged from 80 to 110 mg/dL. We chose not to use a lower target for several reasons. The primary reason was the safety concern that a lower target could potentially increase the risk of hypoglycemia, particularly when the FM algorithm was untested on human patients. Additionally, there is no conclusive evidence or consensus in the literature on an optimal glucose target level for surgical patients. 3, 4 The FM algorithm is fully scalable because the target glucose level and the glucose sampling rate are linearly integrated into the mathematical equations that describe the algorithm. Thus, the FM algorithm is easily scaled to work for different target glucose levels and sampling rates. This is more difficult to achieve with the VA algorithm because it uses a glucose-insulin mapping table that does not directly incorporate either the target glucose level or the sampling rate. Additionally, unlike the VA algorithm, the FM algorithm dynamically adapts to varying insulin sensitivities of different patients and surgical conditions. For these reasons, the FM algorithm could be used more effectively for intensive glucose management when compared with the VA algorithm.
The FM algorithm can be conceivably extended to work intraoperatively, though it was not tested as part of this study. Because our study was the first attempt at applying the FM algorithm in human surgical patients, we chose to initially evaluate it in the less-critical SICU environment. Extending the algorithm to the intraoperative phase when glucose levels could be more variable will be the next logical step. For intraoperative usage, implementing the algorithm as part of an anesthesia information management system decision support module would be a suitable option. This would potentially allow the algorithm to use glucose measurements automatically acquired by the anesthesia information management system to prescribe insulin doses.
Continuous glucose sensors for critical care may become available in the near future. 31, 32 Such sensors would conduct frequent measurement of glucose levels, providing a continuous stream of glucose values. Conventional paperbased algorithms are incapable of using this information on a continuous, real-time basis. On the other hand, a computerized FM algorithm is designed to be integrated with a continuous glucose sensor to perform closed-loop glucose control. Such a system could closely monitor blood glucose levels and deliver optimal and safe glucose control for ICU patients in an automated fashion.
APPENDIX
The FM algorithm is based on a modified proportional derivative method that utilizes a weighted average of proportional and derivative errors. The proportional error is a scaled version of the difference between the actual and desired glucose levels. The derivative error is a scaled version of the rate of change of glucose levels. In mathematical terms, the algorithm can be represented as
where I(t) ϭ insulin infusion, K 0 and K 1 ϭ gain factors, W 0 (t) and W 1 (t) ϭ weighting functions, and the error term e(t) ϭ G(t) Ϫ G s where G(t) ϭ blood glucose levels and G s ϭ desired glucose level. In discrete form, the above equation can be represented as
where the insulin infusion at the current step, I(k), is the weighted sum of glucose errors, e(k), and its first derivative, ë(k), and K e & K de are the proportional and derivative gain factors.
The weighting functions, W 1 (k) and W 2 (k), are defined such that the more recent errors and their derivatives are weighed higher than older errors and their derivatives. Specifically, a normalized exponentially decaying function is used to specify the weighting factors. This approach is similar to a finite impulse response filter and utilizes a fading memory of glucose levels to prescribe an insulin dose. The weighting functions are defined as shown below, where K p and L p define the decaying weight curve for the proportional term and K d and L d define the decaying weight curve for the derivative term. 
Adaptive variation of the gain factors is adopted to account for patient-to-patient variation in body mass, insulin sensitivity, liver sensitivity, and other factors that affect glucoseinsulin interaction. Adaptive tuning is achieved using a performance index, PI(k), that is defined by combining the current glucose error and the first derivative of glucose error:
where the constants R e and R de define the range over which the error or derivative error could vary. The saturation hyperbolic function helps in limiting the variation of PI(k), thus improving algorithm stability. The motivation for using the above performance index is derived from the fact that the desired aim of the control algorithm should be to maintain glucose level at the set point (e ϭ 0) with no fluctuations about the set point (ë ϭ 0). The performance index is used to define a scaling factor, which in turn is used to adaptively modify the proportional and derivative gain factors. The scaling factors for adaptation are defined below, where ␣ p and ␣ d define how aggressive adaptation should occur for the proportional and derivative gains.
In addition to the above proportional and derivative terms, the FM algorithm also incorporates a steady state or basal insulin component. 1 The basal insulin infusion is defined as I ss ͑k͒ ϭ K ss ϫ tanh ͫ G͑k͒ avg Ϫ G low G range ͬ (8) In the above equation, G(k) avg is the average weighted glucose level, G low is the glucose level at which basal insulin infusion is turned off, G range is the range of glucose level over which the basal insulin infusion could vary, and K ss is the gain factor for the basal insulin infusion.
The values of the various parameters used in the algorithm are outlined in Table 4 . 
